Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis
- PDF / 1,545,392 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 81 Downloads / 197 Views
(2020) 18:226
RESEARCH
Open Access
Potential prognostic value of delta-like protein 3 in small cell lung cancer: a metaanalysis Benchao Chen, Heng Li, Chao Liu, Shuting Wang, Feiyue Zhang, Li Zhang, Mingjie Li and Gaofeng Li*
Abstract Background: Current researches have revealed that delta-like protein 3 (DLL3) may be related with prognosis in patients with small cell lung cancer (SCLC). However, this finding remains controversial in small cell lung cancer. This meta-analysis was systematically performed to evaluate the prognostic value of DLL3 in SCLC. Methods: The PubMed, EMBASE and Web of Science databases were retrieved to collect the eligible references. Through Stata 15.0 software, we pooled hazard ratios (HR) with 95% confidence intervals (CI) by using random or fixed-effects models to evaluate the association between DLL3 and SCLC survival results. Results: A total of 6 inter-related studies including 645 patients were qualified. After we removed 1 study, the remaining 5 studies including 601 patients were pooled to testify that high expression of DLL3 was an inferior prognostic for patients with SCLC in Asian populations (HR = 1.37, 95% CI = 1.05, 1.69; I2 = 0.0%, p = 0.000). The pooled results showed that DLL3 might be higher expression in advanced metastasis SCLC in Asian populations (RR = 0.84, 95% CI = 0.71, 0.99; I2 = 44.7%, p = 0.039). But the expression of DLL3 was not correlated with sex (RR = 1.33, 95% CI = 0.98, 1.80; I2 = 0.0%, p = 0.064), smoking history (RR = 1.01, 95% CI = 0.58, 1.75; I2 = 72.1%, p = 0.967) and tumour stage (RR = 0.68, 95% CI = 0.44, 1.05; I2 = 66.6%, p = 0.081). Conclusions: Our meta-analysis confirms that in Asian populations, high expression of DLL3 was a potential poor prognostic biomarker for SCLC and DLL3 highly expressed in advanced stage SCLC in Asian populations. Keywords: Delta-like protein 3, DLL3, Prognostic, Small cell lung cancer, SCLC, Meta-analysis
Introduction Lung cancer has the highest morbidity and mortality of all malignant tumours, which is one of the most common cancers worldwide [1]. The major histologic subtypes of lung cancer are non-small cell lung cancer (NSCLC, 85%) and small cell lung cancer (SCLC, 15%) [2]. SCLC is an invasive, high-grade malignancy with early development and a bad prognosis. Most patients with SCLC are advanced with widespread metastasis when they are diagnosed, and systemic chemotherapy is * Correspondence: [email protected] Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital), Kunming, Yunnan, China
the most effective therapy [3]. Few therapeutic methods are available after SCLC relapse, and the prognosis is especially poor. Therapeutic treatments for patients with SCLC have essentially remained unchanged in recent years [4]. Thus, further research into the mechanism of SCLC and the exploration of new therapeutic targets for SCLC is imperative. Delta-like protein 3 (DLL3) is a transmembrane protein that promotes the development of neuroendocrine tumours t
Data Loading...
